Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2017 | Treatment methods in mantle cell lymphoma

Stephen Robinson • 26 Mar 2017
EBMT 2017
Mantle Cell Lymphoma

Dr. Stephen Robinson of the Bristol Hematology Oncology Centre discusses the treatment methods involved in mantle cell lymphoma (MCL). MCL is a type of non-Hodgkin lymphoma with a relatively poor prognosis. The first-line treatment in response to MCL is an autologous transplant, other treatments include allogeneic transplantation however, there is no definitive treatment plan. A large retrospective study with EBMT was carried out to investigate the efficacy of allogeneic transplantation in MCL and results suggest that it should not be used as a first-line treatment due to evidence of association with significant toxicity. Recorded at the 2017 annual meeting of the European Society for Blood and Marrow Transplantation

More from Stephen Robinson

CAR T-cells in hematological malignancies
1:15
CAR T-cells in hematological malignancies
Stephen Robinson • 14 Apr 2018
Hodgkin lymphoma: when autologous transplant is unsuccessful
1:11
Hodgkin lymphoma: when autologous transplant is unsuccessful
Stephen Robinson • 14 Apr 2018
The future of CAR T-cell therapy
2:30
The future of CAR T-cell therapy
Stephen Robinson • 14 Apr 2018
Autologous stem cell transplantations: BEAM or BEAC?
2:05
Autologous stem cell transplantations: BEAM or BEAC?
Stephen Robinson • 26 Mar 2017

Related Videos

Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
1:00
Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang • 10 Sep 2026
Lessons from the US: treatment access and patient-guided treatment selection in MCL
0:51
Lessons from the US: treatment access and patient-guided treatment selection in MCL
Elise Chong • 10 Sep 2026
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
1:23
BTKi selection in R/R MCL: implications for sequencing non-covalent BTKis
Yucai Wang • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals